Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EnVivo Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

The executives of EnVivo Pharmaceuticals Inc. believe they've assembled a discovery platform that will identify good drug candidates for Alzheimer's disease (AD) and other neurological disorders. The start-up's plan hinges on the ability to insert human genes known to underlie AD into the fruit fly Drosophila, and to use these model organisms to screen for compounds that can ameliorate the condition. EnVivo has an automated way of monitoring flies that develop symptoms that management believes are pertinent to AD in humans.

You may also be interested in...



Where Are They Now? Checking In With Four Alzheimer’s Disease Start-Ups

Four start-ups previously profiled in START-UP – CoMentis, EnVivo Pharmaceuticals, Avid Radiopharmaceuticals and AC Immune SA – show how some biotechs have successfully ridden through the rough patches any company brave enough to tackle Alzheimer’s disease will likely face.

Addressing Alzheimer's

Fresh insights and tools are empowering start-ups pursuing treatments for Alzheimer's disease.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC090934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel